Condition: Infrapopliteal Lesions · Critical Limb Ischemia · Sponsor: Biotyx Medical (Shenzhen) Co., Ltd.
The goal of this prospective, multicentre, single arm clinical trial is to assess the safety and effectiveness of Sirolimus-eluting Iron Bioresorbable Peripheral Scaffold System (IBS Titan™) in treating patients with infrapopliteal arterial stenosis or occlusive disease. 100 participants will be implanted with IBS Titan™, and be followed up for 1-month, 6-month and 12-month after discharge.
This description comes directly from the study's public registry record.
Ying Xia · 0755 23221096 · xiaying@lifetechmed.com
Always discuss trial participation with your own doctor first.
| Azienda Ospedaliero Universitaria Careggi | Florence, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05971394